SEARCH

SEARCH BY CITATION

References

  • 1
    Farrell GC. The liver and the waistline: Fifty years of growth. J Gastroenterol Hepatol 2009; 24( Suppl 3): S105S118.
  • 2
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. HEPATOLOGY 2007; 45: 846854.
  • 3
    Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 14611465.
  • 4
    Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet 2008; 83: 520528.
  • 5
    Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 282291 e281.
  • 6
    Koritschoner NP, Bocco JL, Panzetta-Dutari GM, Dumur CI, Flury A, Patrito LC. A novel human zinc finger protein that interacts with the core promoter element of a TATA box-less gene. J Biol Chem 1997; 272: 95739580.
  • 7
    Lalazar A, Wong L, Yamasaki G, Friedman SL. Early genes induced in hepatic stellate cells during wound healing. Gene 1997; 195: 235243.
  • 8
    Ratziu V, Lalazar A, Wong L, Dang Q, Collins C, Shaulian E, et al. Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. Proc Natl Acad Sci U S A 1998; 95: 95009505.
  • 9
    Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 2007; 26: 44284434.
  • 10
    Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005; 65: 12131222.
  • 11
    Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005; 65: 57615768.
  • 12
    Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest 2008; 118: 27112721.
  • 13
    Clement K, Pueyo ME, Vaxillaire M, Rakotoambinina B, Thuillier F, Passa P, et al. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia 1996; 39: 8290.
  • 14
    Tappy L, Dussoix P, Iynedjian P, Henry S, Schneiter P, Zahnd G, et al. Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene. Diabetes 1997; 46: 204208.
  • 15
    Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, Natali A, et al. The EGIR-RISC STUDY (the European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk). I. Methodology and objectives. Diabetologia 2004; 47: 566570.
  • 16
    Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539548.
  • 17
    Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368377.
  • 18
    Leow CC, Wang BE, Ross J, Chan SM, Zha J, Carano RA, et al. Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway. J Biol Chem 2009; 284: 2105721065.
  • 19
    Dardevet D, Moore MC, Remond D, Everett-Grueter CA, Cherrington AD. Regulation of hepatic metabolism by enteral delivery of nutrients. Nutr Res Rev 2006; 19: 161173.
  • 20
    Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, et al. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 2009; 52: 61426152.
  • 21
    Agius L. Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks. Diabetes 2009; 58: 1820.
  • 22
    Chiu KC, Chuang LM, Yoon C, Saad MF. Hepatic glucokinase promoter polymorphism is associated with hepatic insulin resistance in Asian Indians. BMC Genet 2000; 1: 2.
  • 23
    Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008; 414: 118.
  • 24
    Postic C, Magnuson MA. DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 2000; 26: 149150.
  • 25
    Gkretsi V, Apte U, Mars WM, Bowen WC, Luo JH, Yang Y, et al. Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly. HEPATOLOGY 2008; 48: 19321941.
  • 26
    Reyes A, Cardenas ML. All hexokinase isoenzymes coexist in rat hepatocytes. Biochem J 1984; 221: 303309.
  • 27
    Wu JC, Merlino G, Fausto N. Establishment and characterization of differentiated, nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth factor alpha. Proc Natl Acad Sci U S A 1994; 91: 674678.
  • 28
    Kim TH, Kim H, Park JM, Im SS, Bae JS, Kim MY, et al. Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver. J Biol Chem 2009; 284: 1507115083.
  • 29
    McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255262.
  • 30
    Visser ME, Lammers NM, Nederveen AJ, van der Graaf M, Heerschap A, Ackermans MT, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 2011; 54: 21132121.
  • 31
    Li X, Zhao Q, Wu K, Fan D. I148M variant of PNPLA3 confer increased risk for nonalcoholic fatty liver disease not only in European population, but also in Chinese population. HEPATOLOGY 2011.
  • 32
    Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. HEPATOLOGY 2010; 52: 904912.
  • 33
    Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 15671576, 1576 e1561–1566.
  • 34
    Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
  • 35
    Sotaniemi EA, Keinanen K, Lahtela JT, Arranto AJ, Kairaluoma M. Carbohydrate intolerance associated with reduced hepatic glucose phosphorylating and releasing enzyme activities and peripheral insulin resistance in alcoholics with liver cirrhosis. J Hepatol 1985; 1: 277290.
  • 36
    Lowes W, Walker M, Alberti KG, Agius L. Hexokinase isoenzymes in normal and cirrhotic human liver: suppression of glucokinase in cirrhosis. Biochim Biophys Acta 1998; 1379: 134142.
  • 37
    Davis EA, Cuesta-Munoz A, Raoul M, Buettger C, Sweet I, Moates M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999; 42: 11751186.
  • 38
    Massa O, Meschi F, Cuesta-Munoz A, Caumo A, Cerutti F, Toni S, et al. High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetes (SIEDP). Diabetologia 2001; 44: 898905.
  • 39
    Miller SP, Anand GR, Karschnia EJ, Bell GI, LaPorte DC, Lange AJ. Characterization of glucokinase mutations associated with maturity-onset diabetes of the young type 2 (MODY-2): different glucokinase defects lead to a common phenotype. Diabetes 1999; 48: 16451651.
  • 40
    Cuesta-Munoz AL, Tuomi T, Cobo-Vuilleumier N, Koskela H, Odili S, Stride A, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCK-MODY). Diabetes Care 2010; 33: 290292.
  • 41
    Holian J, Qi W, Kelly DJ, Zhang Y, Mreich E, Pollock CA, et al. Role of Kruppel-like factor 6 in transforming growth factor-beta1-induced epithelial-mesenchymal transition of proximal tubule cells. Am J Physiol Renal Physiol 2008; 295: F13881396.
  • 42
    Farrelly D, Brown KS, Tieman A, Ren J, Lira SA, Hagan D, et al. Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation. Proc Natl Acad Sci U S A 1999; 96: 1451114516.
  • 43
    Chu CA, Fujimoto Y, Igawa K, Grimsby J, Grippo JF, Magnuson MA, et al. Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats. Am J Physiol Gastrointest Liver Physiol 2004; 286: G627634.
  • 44
    Grimsby J, Coffey JW, Dvorozniak MT, Magram J, Li G, Matschinsky FM, et al. Characterization of glucokinase regulatory protein-deficient mice. J Biol Chem 2000; 275: 78267831.
  • 45
    Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 2001; 56: 195217.
  • 46
    Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999; 274: 305315.
  • 47
    Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, Li JZ, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res 2011; 52: 318329.
  • 48
    Sparso T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008; 51: 7075.
  • 49
    Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 13311336.
  • 50
    Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008; 57: 31123121.
  • 51
    Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18: 40814088.